Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These changes are mirrored in serum and should be considered in the light of the downmodulating role of CD26 in major chemokines related to the pathogenesis of asthma such as CCL11 (eotaxin), CCL5 (RANTES), and CXCL12a (SDF-1α).
|
29297467 |
2019 |
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
No differences in the release or expression of RANTES, IFN-λ1 protein and mRNA, or IFN-α and IFN-β mRNA between asthmatics and healthy controls were observed.
|
29411555 |
2018 |
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This study was aimed to determine the profiles of serum cytokines (IL-1β, TNF-α, IL-4, IL-5) and chemokines (MCP-1: monocyte chemoattract protein-1 and RANTES: regulated on activation normal T cell expressed and secreted) in individuals with an asthmatic versus a non-asthmatic background with bacterial, viral or mixed acute respiratory infection.
|
28168862 |
2017 |
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings suggest that HRV-induced CCL5 can induce ASMC chemotaxis and thus may contribute to the pathogenesis of airway remodeling in patients with asthma.
|
28257236 |
2017 |
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that the CCL5 -28C/G polymorphism is a risk factor for asthma.
|
25898691 |
2015 |
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Association between RANTES gene polymorphisms and asthma: a meta-analysis.
|
24963658 |
2014 |
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Carriers of both IL-13 A2044G A/A and RANTES G-28C G/G have a more significant risk for developing asthma than those with only a single polymorphism.
|
24053708 |
2013 |
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The current cluster analysis identified meaningful adult asthma phenotypes linked to the functional CCL5 and ADRB2 genotypes.
|
23267209 |
2013 |
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Treatment with NOD1,2 ligand could induce the subepithelial fibrosis and significantly enhance the serum concentration of total IgE, chemokine CCL5 for eosinophils and T helper type 2 (Th2) cells and asthma Th2 cytokine IL-13 in bronchoalveolar lavage fluid of ovalbumin-sensitized allergic asthmatic mice (all P<0.05).
|
23524653 |
2013 |
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The presence of increased CCL5 levels in nasal epithelia at the time of bronchiolitis or the development of allergic sensitization by age 3 years are associated with increased likelihood of subsequent asthma.
|
22444510 |
2012 |
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Previous studies revealed that polymorphisms of RANTES were implicated in susceptibility to asthma, but a large number of studies reported apparently conflicting results.
|
20430255 |
2010 |
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A number of studies have evaluated the functional polymorphism -28C/G in the RANTES promoter region, which had been found to affect the transcription of the RANTES gene, in relation to asthma susceptibility.
|
20186291 |
2010 |
Asthma
|
0.600 |
Biomarker
|
disease |
RGD |
Role of the extracellular signal-regulated kinase 1/2 signaling pathway in regulating the secretion of bronchial smooth muscle cells in a rat model of chronic asthma.
|
18208670 |
2008 |
Asthma
|
0.600 |
Biomarker
|
disease |
LHGDN |
It was previously reported that the gain-of-function -28 guanine allele of the promoter single nucleotide polymorphism (SNP; cytosine to guanine substitution of nucleotide -28 (-28C>G)) in the CC chemokine ligand 5 gene (CCL5) was associated with susceptibility to late-onset asthma in patients who developed asthma at age > or =40 yrs.
|
18385174 |
2008 |
Asthma
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
The polymorphisms within the RANTES promoter may have a disease-modifying effect in Korean children with asthma.
|
17990036 |
2008 |
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The polymorphisms within the RANTES promoter may have a disease-modifying effect in Korean children with asthma.
|
17990036 |
2008 |
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our objective was to investigate the possible influence of the CCL5/RANTES promoter polymorphisms in the different types of bronchial asthma.
|
18186796 |
2008 |
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
C-C chemokines such as CCL11, CCL5, and CCL3 are central mediators in the pathogenesis of asthma.
|
18178867 |
2008 |
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
It was previously reported that the gain-of-function -28 guanine allele of the promoter single nucleotide polymorphism (SNP; cytosine to guanine substitution of nucleotide -28 (-28C>G)) in the CC chemokine ligand 5 gene (CCL5) was associated with susceptibility to late-onset asthma in patients who developed asthma at age > or =40 yrs.
|
18385174 |
2008 |
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
There was a weak and negative correlation between T-bet expression and RANTES level in the asthmatics (r=-0 x 29, P=0 x 032).
|
17302903 |
2007 |
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that -28 C/G and -403 G/A polymorphisms within the RANTES promoter region play an important role in asthma predisposition and in the severity of airway obstruction.
|
17678722 |
2007 |
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
RANTES is genetically associated with asthma, sarcoidosis and multiple sclerosis.
|
16855620 |
2006 |
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although there are several reports on the association of RANTES promoter polymorphisms (-403G/A and -28C/G) with asthma, the association of these polymorphisms with atopic dermatitis has not yet been confirmed in other populations.
|
17117952 |
2006 |
Asthma
|
0.600 |
Biomarker
|
disease |
LHGDN |
RANTES production from mononuclear cells in response to the specific allergen in asthma patients.
|
17075265 |
2006 |
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We studied 61 patients with asthma and/or atopy and 129 to 157 newborn controls for the -403 RANTES, -28 RANTES, and -1055 IL-13 SNPs, as well as 47 patients and 60 newborn controls for the -444 LTC4S SNP.
|
16024972 |
2005 |